|
C13ORF34 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.99680288865056E-15 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
6.68354260824344E-14 |
| Normal-vs-Stage3 |
1.62458935193399E-12 |
| Normal-vs-Stage4 |
1.64546154479694E-12 |
| Stage1-vs-Stage2 |
2.335800E-01 |
| Stage1-vs-Stage3 |
1.128200E-02 |
| Stage1-vs-Stage4 |
4.308200E-02 |
| Stage2-vs-Stage3 |
5.023000E-01 |
| Stage2-vs-Stage4 |
4.984000E-01 |
| Stage3-vs-Stage4 |
8.700200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.77555756156289E-15 |
| Normal-vs-AfricanAmerican |
1.30095934025576E-12 |
| Normal-vs-Asian |
6.48109999001889E-09 |
| Caucasian-vs-AfricanAmerican |
1.899180E-01 |
| Caucasian-vs-Asian |
5.782500E-02 |
| AfricanAmerican-vs-Asian |
2.913700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62714286489063E-12 |
| Male-vs-Female |
5.329600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62525548574877E-12 |
| Normal-vs-Age(61-80Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(81-100Yrs) |
9.61280000000286E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.677700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.088400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.927400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.529400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.704400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.543000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.298400E-02 |
| Classical-VS-Follicular |
7.500800E-01 |
| Classical-VS-Other |
3.714800E-01 |
| Classical-VS-Normal |
1.80444548192327E-12 |
| Tall-VS-Follicular |
1.014180E-01 |
| Tall-VS-Other |
8.500400E-01 |
| Tall-VS-Normal |
3.37507799486048E-14 |
| Follicular-VS-Other |
4.895400E-01 |
| Follicular-VS-Normal |
1.63513647066793E-12 |
| Other-VS-Normal |
1.171800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.63236091310637E-12 |
| N0-vs-N1 |
4.348000E-01 |
|
|
